Oryzon Genomics SA represents core values of innovation, integrity, and collaboration. This biopharmaceutical company is committed to advancing precision medicine through cutting-edge research and development. With a focus on epigenetics, Oryzon Genomics SA aims to discover and develop novel therapies for serious diseases such as cancer and neurodegenerative disorders. The company's corporate philosophy revolves around ethically transforming scientific knowledge into tangible solutions for patients worldwide. By fostering partnerships and leveraging its expertise, Oryzon Genomics SA strives to bring about meaningful advancements in the field of personalized medicine.

Oryzon Genomics SA is primarily present in Spain and the United States.

Oryzon Genomics SA has achieved several significant milestones. The company successfully completed various clinical trials, including Phase II and Phase IIB studies, for its lead investigational drug, vafidemstat. They have also garnered positive results in these trials, demonstrating the drug's potential for the treatment of various neurological and psychiatric disorders. Oryzon Genomics SA has secured several partnerships and collaborations with renowned institutions and pharmaceutical companies to further advance their research and development efforts. They have also received important regulatory designations, such as Orphan Drug Designation from the U.S. FDA, further validating the potential of their innovative therapies.

Oryzon Genomics SA is a biopharmaceutical company specializing in epigenetics and precision medicine. Founded in 2000, the Spanish-based company emerged from a joint initiative of scientists and researchers from the University of Barcelona and the Spanish National Research Council. Oryzon Genomics focuses on the development of innovative therapies for serious diseases, such as cancer and neurological disorders, by modulating gene expression through epigenetic mechanisms. They employ cutting-edge technologies and have a robust pipeline of investigational drugs under development. Oryzon Genomics aims to bring novel and effective treatment options to patients and contribute to advancing the field of precision medicine.

Some of the main competitors of Oryzon Genomics SA in the market include other companies in the field of biotechnology and pharmaceuticals. These can include companies like Roche Holding AG, Novartis AG, and Amgen Inc.

Oryzon Genomics SA is primarily active in the biotechnology industry.

The business model of Oryzon Genomics SA revolves around the development and commercialization of innovative epigenetic therapies. As a biopharmaceutical company, Oryzon focuses on the research and discovery of new drugs to treat diseases associated with altered gene expression. By targeting specific epigenetic marks, they aim to regulate gene activity and restore normal cellular function. Oryzon Genomics SA collaborates with academic institutions and pharmaceutical companies to advance their therapies through preclinical and clinical development stages. With a focus on epigenetics, Oryzon strives to provide novel therapeutic solutions for diseases such as cancer, neurological disorders, and autoimmune conditions.

Oryzon Genomics KGV ir -32,54.

Oryzon Genomics KUV ir 62,05.

AlleAktien kvalitātes vērtējums Oryzon Genomics ir 2/10.

gaidāmā Oryzon Genomics apgrozījums ir 1,87 milj. EUR.

gaidāmā Oryzon Genomics peļņa ir -3,56 milj. EUR.

Oryzon Genomics SA is a biotechnology company specializing in the development of epigenetic-based therapies for neurodegenerative diseases and cancer. The company is headquartered in Spain and has been listed on the Madrid Stock Market since 2015. Oryzon Genomics SA's business model includes several divisions, each with a specific focus to achieve Oryzon's goal of providing innovative therapies for severe and chronic diseases. The main focus is on identifying enzymes involved in epigenetic changes that contribute to the onset of certain diseases. These enzymes are intended to serve as targets for the development of new drugs. The first division of Oryzon Genomics SA is the research and development of drugs. The company has various programs in the field of epigenetics focused on the development of therapeutics for severe diseases. This includes programs for Alzheimer's disease, multiple sclerosis, autism, depression, and various types of cancer. The company focuses on the discovery of new drug classes and works closely with academic institutions and pharmaceutical companies. Another important division of Oryzon is the Mechanism-of-Action (MOA) service. This service helps other pharmaceutical companies understand the mode of action of new drugs. Oryzon offers its service for the analysis of potential drug effectiveness and assists in identifying new therapeutic target structures. This is intended to enable other pharmaceutical companies to develop new drugs more quickly. The company also has a Clinical Development Unit that focuses on the clinical development of new drugs. In this division, data from animal studies and Phase I areas are used to test the efficacy and safety of compounds in clinical trials. The clinical development of drugs is a time-consuming and costly process, but it is also a crucial phase for the approval of a new drug. Another important area of Oryzon Genomics is its service business. Here, the company offers its expertise and experience in epigenetics to assist other pharmaceutical companies and academic institutions in the development of new drugs and diagnostics. The services offered include drug discovery services, analytical and preclinical services, molecular biology and epigenetic services, and assay development services. Finally, the company also offers products such as epigenetic kits and reagents for research. These products are intended to help scientists better understand the mechanisms of epigenetics and develop new therapeutic approaches. In summary, Oryzon Genomics SA's business model is focused on developing innovative therapies for severe and chronic diseases. The company identifies enzymes involved in epigenetic changes and uses them as targets for new drugs. The company has several divisions, including research and development, the MOA service, the Clinical Development Unit, and the service business. Oryzon Genomics SA also offers products such as epigenetic kits and reagents for research and strives to advance the development of new therapeutic approaches in epigenetics.

Oryzon Genomics izmaksā dividendes 0 EUR, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Oryzon Genomics vai uzņēmums nedod dividendes.

Oryzon Genomics ISIN ir ES0167733015.

Oryzon Genomics WKN ir A2ACV2.

Oryzon Genomics simbols ir ORY.MC.

Pēdējo 12 mēnešu laikā Oryzon Genomics maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Oryzon Genomics plāno maksāt dividendes 0 EUR apmērā.

Oryzon Genomics pašreizējā dividendu rentabilitāte ir .

Oryzon Genomics maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Oryzon Genomics pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 EUR. Tas atbilst dividendes ražībai 0 %.

Oryzon Genomics tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Oryzon Genomics apmērā 0 EUR, kas tika izmaksāta 16.07.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 16.07.2024..

Pēdējās dividendes izmaksa notika 16.07.2024..

Gadā 2023, Oryzon Genomics izmaksāja 0 EUR dividendes.

Oryzon Genomics dividendes tiek izmaksātas EUR.